Skip to main content

Boundless Bio to Present at the Guggenheim Oncology Conference

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary Hornby, will present at the Guggenheim Oncology Conference, which will take place virtually. Presentation details are as follows:

Date: Friday, February 11, 2022

Time: 2:00 PM – 2:25 PM EST

About Boundless Bio

Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and Twitter.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  216.64
+7.91 (3.79%)
AAPL  263.31
-0.44 (-0.17%)
AMD  201.47
+10.52 (5.51%)
BAC  50.08
+0.11 (0.21%)
GOOG  303.01
-0.55 (-0.18%)
META  670.40
+15.32 (2.34%)
MSFT  408.99
+5.06 (1.25%)
NVDA  184.17
+4.12 (2.29%)
ORCL  153.08
+4.07 (2.73%)
TSLA  406.32
+13.89 (3.54%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.